Drug intelligence / Profile preview

WGI-0047

Development stage: Preclinical
Lead developer: Haichang Biotech
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

WGI-0047 (also known as MyHIF) is an antisense oligonucleotide (ASO) therapeutic being developed by The WhiteOak Group for the treatment of small cell lung carcinoma (SCLC). The drug is designed to inhibit the expression of hypoxia-inducible factor 1-alpha (HIF-1-alpha), a transcription factor that plays a critical role in tumor adaptation to hypoxic environments, promoting angiogenesis, metabolic reprogramming, and cell survival. WGI-0047 utilizes a proprietary lipid nanoparticle delivery system known as QTsome to facilitate the systemic delivery and cellular uptake of the antisense sequence. It is currently in the IND-enabling/preclinical stage of development.

Other names: MyHIF

Targets

HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on WGI-0047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WGI-0047.

Explore the full profile